KROS Live signaler | Maksimer profitt med Getagraph.com

SELG 102502 min ago

@ $58.15

Utstedt: 14 feb 2024 @ 21:11

Avkastning: -6.81%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: 4.68 %

Live Chart Being Loaded With Signals

Commentary (25 apr 2024 @ 22:00):

Stats
Dagens volum	253 154
Gjennomsnittsvolum	370 829
Markedsverdi	1.95B
EPS	$-1.340 ( 2024-03-01 )
Neste inntjeningsdato	( $-1.310 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.42
ATR14	$0.101 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Seehra Jasbir	Buy	125 000	Employee Stock Option (right to buy)
2024-02-13	Seehra Jasbir	Buy	125 000	Employee Stock Option (right to buy)
2024-02-13	Regnante Keith	Buy	40 000	Employee Stock Option (right to buy)
2024-02-13	Rovaldi Christopher	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Cooper Simon Peter	Buy	40 000	Employee Stock Option (right to buy)

INSIDER POWER
67.58
Last 96 transactions
Buy: 1 546 013 \| Sell: 365 314

Volum Korrelasjon

Lang: -0.12 (neutral)

Kort: 0.73 (moderate)

Signal:(52.024) Neutral

Keros Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
PRAX	0.919
CDNA	0.904
HNNA	0.894
RPAY	0.889
TTEC	0.888
EWTX	0.883
SMSI	0.882
SRAX	0.879
ANNX	0.876
LPCN	0.874

10 Mest negative korrelasjoner
CNST	-0.811
UNCY	-0.801

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Keros Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.17
( neutral )

-0.02
( neutral )

0.00
( neutral )

0.06
( neutral )

-0.31
( neutral )

0.50
( neutral )

Keros Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$151 000
Bruttogevinst:	$-664 000 (-439.74 %)
EPS:	$-5.20

Q4	2023
Omsetning:	$143 000
Bruttogevinst:	$-104 000 (-72.73 %)
EPS:	$-1.340

Q3	2023
Omsetning:	$8 000.00
Bruttogevinst:	$-543 000 (-6 787.50 %)
EPS:	$-1.330

Q2	2023
Omsetning:	$0
Bruttogevinst:	$-545 000 (0.00 %)
EPS:	$-1.270

Financial Reports:

No articles found.

Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.